好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study
Neuro-oncology
P1 - Poster Session 1 (5:30 PM-6:30 PM)
7-009

We sought to identify demographic, admission and discharge characteristics of patients with known primary brain tumors (PBTs) admitted to our neurological intensive care unit (ICU). 

A paucity of data exists that describe outcomes of PBT patients admitted to an ICU in the United States.  ICUs are reluctant to admit these patients due to the presumption that they will do poorly. 

This is a single institution retrospective analysis of adult patients with PBTs admitted to an ICU at Duke University Hospital between 7/1/13 – 4/12/18.  Patients were identified from DUMC’s neurocritical care and brain tumor databases. Patient demographics, tumor characteristics, admission diagnoses, disposition and survival data were collected from the databases and medical record review.  Descriptive analysis was performed.  Survival time was determined from date of admission to ICU to date of death.  

247 patient encounters were identified; however, 147 were excluded due to a length of stay ≤2 days (predominantly patients admitted for elective resection), resulting in 100 patient encounters that were included in the analysis.  There was a total of 94 patients who comprised the 100 encounters.  The predominant histologic diagnosis was glioblastoma (WHO grade IV) (n=62, 62%).  The mean age was 34 yrs (range 19-78).  35 unique diagnoses for admission were identified.  The most common admission indications were for clinical trial related catheter infusions (n=33, 33%) and status epilepticus (n=11, 11%).  Among the 67 encounters that were not clinical trial related, the discharge disposition of patients was: 11 expired, 8 discharged to hospice, 2 to long-term care, 20 to rehabilitation facility, and 26 home.  Median survival time for all patients was 370 days (95% CI: 246-511). 

This is the first descriptive analysis of patients in the United States with PBTs admitted to an ICU.  The majority of patients had a favorable discharge disposition.

 

Authors/Disclosures
Jennifer Kang, MD (Kaiser Permanente)
PRESENTER
Dr. Kang has nothing to disclose.
Christa B. Swisher, MD (Duke University Medical Center) Dr. Swisher has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB.
No disclosure on file
No disclosure on file
Eric Lipp No disclosure on file
No disclosure on file
Margaret O. Johnson, MD (Duke University Medical Center) Dr. Johnson has nothing to disclose.
No disclosure on file
Annick DesJardins, MD (Duke University Medical Center) Dr. DesJardins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orbus Therapeutics. Dr. DesJardins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biodexa. Dr. DesJardins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telix Therapeutics. Dr. DesJardins has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chimerix. Dr. DesJardins has stock in Istari Oncology. Dr. DesJardins has received intellectual property interests from a discovery or technology relating to health care.
Dina Randazzo, DO No disclosure on file
No disclosure on file
Katherine B. Peters, MD, PhD, FAAN (Duke University Medical Center) Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sapience. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ONO Pharmaceutical. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telix. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AnHeart. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rigel. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nuvation. The institution of Dr. Peters has received research support from Biomimetix. The institution of Dr. Peters has received research support from Servier. The institution of Dr. Peters has received research support from Varian. The institution of Dr. Peters has received research support from Sapience. The institution of Dr. Peters has received research support from Ono Pharmaceuticals/Deciphera. The institution of Dr. Peters has received research support from Nuvation. The institution of Dr. Peters has received research support from Novocure. The institution of Dr. Peters has received research support from Curis.